ArticleFrontiers in cellular and infection microbiology2017
Enrofloxacin and Toltrazuril Are Able to Reduce
Article in Frontiers in cellular and infection microbiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 44 citations in OpenAlex.
- Quinolones as anti-Toxoplasma agents: a comprehensive scoping review of in vitro and in vivo efficacy.Parasitology research · 2026Article
- Quercetin ReducesInternational journal of molecular sciences · 2026Article
- Cytotoxicity and Antiparasitic Effects of Toltrazuril Against Enteromyxum leei in Olive Flounders: In Vitro and In Vivo Analyses.Journal of fish diseases · 2025Article
- New derivatives of 6-nitrocoumarin-3-thiosemicarbazone exhibit improved antiparasitic activity in the placenta againstAntimicrobial agents and chemotherapy · 2025Article
- Prenylated chalcone analog-mediated Inhibition of Toxoplasma gondii growth in human trophoblast cell line and villous explants.Scientific reports · 2025Article
- Article
- In Vitro Evaluation of Anti-Parasitic Activities of Quinolone-Coumarin Hybrids Derived from Fluoroquinolones and Novobiocin Against Toxoplasma gondii.Acta parasitologica · 2024Article
- Polyalthic Acid fromPharmaceuticals (Basel, Switzerland) · 2023Article
- Article
- Leaf hydroalcoholic extract and oleoresin fromFrontiers in cellular and infection microbiology · 2023Article
- Antimicrobial, Antivirulence, and Antiparasitic Potential ofAntibiotics (Basel, Switzerland) · 2022Article
- Placental Models for Evaluation of Nanocarriers as Drug Delivery Systems for Pregnancy Associated Disorders.Biomedicines · 2022Review
- Unifying Virulence Evaluation inFrontiers in cellular and infection microbiology · 2022Review
- Cyclooxygenase (COX)-2 modulates Toxoplasma gondii infection, immune response and lipid droplets formation in human trophoblast cells and villous explants.Scientific reports · 2021Article
- In vivo and in vitro models show unexpected degrees of virulence among Toxoplasma gondii type II and III isolates from sheep.Veterinary research · 2021Article
- Copaifera spp. oleoresins impair Toxoplasma gondii infection in both human trophoblastic cells and human placental explants.Scientific reports · 2020Article
- Anti-Research in pharmaceutical sciences · 2020Article
- Modeling the Ruminant Placenta-Pathogen Interactions in Apicomplexan Parasites: Current and Future Perspectives.Frontiers in veterinary science · 2020Review
- Biogenic Silver Nanoparticles Can ControlFrontiers in microbiology · 2020Article
- Susceptibility of human villous (BeWo) and extravillous (HTR-8/SVneo) trophoblast cells to Toxoplasma gondii infection is modulated by intracellular iron availability.Parasitology research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Classical treatment for congenital toxoplasmosis is based on combination of sulfadiazine and pyrimethamine plus folinic acid. Due to teratogenic effects and bone marrow suppression caused by pyrimethamine, the establishment of new therapeutic strategies is indispensable to minimize the side effects and improve the control of infection. Previous studies demonstrated that enrofloxacin and toltrazuril reduced the incidence of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.